Daily Stock List
Colombia Energy Resources, Inc. (CERX)
SmallCapVoice and Street Beat reported earlier on Colombia Energy Resources, Inc. (CERX), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Based in San Francisco, California, Colombia Energy Resources, Inc. is a metallurgical coal exploration and mining company. They are exploring coal deposits and developing coalmines at Company controlled mining concessions in the interior region of Colombia. The Republic of Colombia is the world's tenth largest producer and fourth largest exporter of coal. The Company is operating and building metallurgical coalmines in Colombia, with a targeted production of one million tons-per-annum by 2015. They plan to develop coke manufacturing facilities based on proven, efficient and environmentally friendly technologies that they plan to bring to Colombia.
The Company's team of executives, advisors, and partners consists of experienced entrepreneurs and business professionals in the U.S. and Colombia with major experience in coal mining and clean coal technologies as well as substantial industry relationships. Colombia Energy Resources operates in Colombia by way of their wholly owned subsidiary Colombia Clean Power S.A.S.
The Company has acquired coal deposits, are operating and building metallurgical coalmines and coke plants, and plans to become a leading consolidator in the Colombian metallurgical coal market. Their plan is to import international mining best practices and proven, advanced, and environmentally friendly coke processing technologies to Colombia, as they become a leading consolidator in the Colombian metallurgical coal market.
They own and control mining concessions in the provinces of Boyaca and Santander. These were selected because of their large metallurgical coal resources and their location near the Magdalena River, which is expected in the near future to be a major shipping route for their coal to the export markets.
Colombia Energy Resources controls ten coal mining concessions contracts, covering 12,000 hectares (approximately 29,600 acres), in the districts of Boyaca and Santander. At Ruku, Boyaca, they control two coal concessions and one application with 80 hectares (198 acres). They recently signed an agreement to purchase an adjacent concession with 17 hectares (42 acres).
At Boavita, Boyaca, they signed an option agreement to purchase a concession with 1,550 hectares (3,830 acres), pending satisfactory results of an exploration program. They also signed an agreement to develop and operate mines on the property in advance of exercising the purchase option. At Otanche, Boyaca, they have 3,283 hectares (8,113 acres).
Additionally, at North Block, Santander, they own three concessions with 7,074 hectares (17,481 acres). The Company is evaluating several additional properties in Boyaca, Cundinamarca, Santander and Norte Santander.
Colombia Energy Resources, Inc. (CERX), closed Tuesday's trading session at $0.14, down 17.65%, on 1,340 volume with 3 trades. The average volume for the last 60 days is 4,564 and the stock's 52-week low/high is $0.21/$1.70.
Dex One Corp. (DEXO)
TheStockfather, Stock Analyzer, RedChip, AllPennyStocks, StreetInsider, ChartPoppers, and Greenbackers reported earlier on Dex One Corp. (DEXO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Dex One Corp. is a leading marketing solutions provider helping local businesses and their customers connect - wherever and whenever they choose to search. The Company's heritage is delivering print-based solutions. They are building on this heritage by providing integrated products and services to help their clients establish their digital presence and generate leads. Dex One lists on the NYSE Market. The Company has their corporate headquarters in Cary, North Carolina.
Dex One's locally based marketing experts offer an extensive network of local marketing solutions. These include online, mobile and print search solutions, such as DexKnows.com. The Company provides smart, searchable advertising, free marketing consultations, and expert online resources. The design of all of these is to help local businesses get found and chosen by new customers.
Through Dex One, a client starts with a dedicated local marketing consultant. They receive a personalized marketing plan based on real data. They build their local presence and place custom-created advertising in the most visible places - online as well as offline. The Company has nearly 1,500 Dex One marketing consultants serving hundreds of communities across the United States.
Dex One offers integrated online and print solutions covering every vital marketing channel. These include Search Engines, Websites,
Directories, Reputation Management, Videos, Display Ads, and Reports. Their offline presence includes print directory advertising and QR codes. The Company's network includes Google, Yahoo, Bing™, YouTube, DexKnows.com, YP.com(SM), and others.
This month, Dex One announced that the Company received the 2012 Eloqua Markie Rookie of the Year award for excellence in digital marketing, featuring their "How Findable Are You?" campaign. Dex One received recognition during an awards ceremony at Eloqua Experience on Nov. 7, 2012, Eloqua's annual user conference.
Dex One was honored for their customer-centric, automated demand generation campaign that used the Eloqua platform. Eloqua's cloud software, professional services and education programs provide marketers with the technology and expertise needed to help marketing drive revenue.
Dex One Corp. (DEXO), closed Tuesday's trading session at $0.88, up 7.86%, on 624,204 volume with 536 trades. The average volume for the last 60 days is 432,754 and the stock's 52-week low/high is $0.66/$2.48.
International Datacasting Corp. (IDC.TO)
Today we are reporting on International Datacasting Corp. (IDC.TO), here at the QualityStocks Daily Newsletter.
Listed on the Toronto Stock Exchange, International Datacasting Corp. (IDC) is an international leader in digital content distribution for the world's premier broadcasters in radio, television, data and digital cinema. They offer a broad portfolio of advanced solutions including Pro Audio, Pro Video, Pro Cinema, and Pro Data for implementing broadcast content contribution and distribution applications. IDC is based in Ottawa, Ontario.
IDC has more than 15 years' experience in delivering professional MPEG video contribution encoding platforms and has more than 5,000 installations globally. The Company has regional offices in Arnhem, the Netherlands and in San Diego, California. They develop and manufacture hardware and software at their Ottawa, Ontario factory.
IDC has partnered with key customers in the core markets of radio, data, video and digital cinema. These include Thomson, CBS Westwood One, National Public Radio, AccessIT, SES Americom, TVN, EchoStar, Arqiva, and Deluxe, among others. IDC is a member of the Digital Video Broadcasting (DVB) Organization, Ottawa Centre for Research and Innovation (OCRI), and the National Association of Broadcasters (NAB).
IDC's products and solutions are in demand for radio and television networks, digital cinema, 3D live events, distance learning, satellite news gathering, sport contribution, ad insertion, VOD, and IPTV among others. The Company has installations in more than 100 countries and service offices in Australia, Singapore and China with a worldwide network of value-added partners and distributors. IDC has an extensive portfolio of advanced technology products marketed under the names SuperFlex, Datacast XD, Tiernan, Logic Innovations and PROFline.
This past September, IDC announced the unveiling of what they believe is a significant evolution in professional video contribution. The HMR5542 Professional Video Receiver underwent development to complement the Company's leading TITAN MPEG Video Encoder for advanced content contribution for television programming. The HMR5542 Professional Video Receiver is a compact, multi-format professional IRD. The design of the HMR5442 receiver is for use in professional broadcast contribution and distribution applications where multiple video formats (SD and HD), interface flexibility (Satellite and IP) and content protection (BISS) are needed.
International Datacasting Corp. (IDC.TO), closed Tuesday's trading session at $0.175, up 2.94%, on 41,139 volume. The stock's 52-week low/high is $0.17/$0.35.
Rathdowney Resources Ltd. (RTH.V)
We are highlighting Rathdowney Resources Ltd.(RTH.V), here at the QualityStocks Daily Newsletter.
Rathdowney Resources Ltd. is a mineral exploration and development company whose shares trade on the TSX Venture Exchange. The Company concentrates on finding and developing the next generation of zinc deposits. Rathdowney Resources is associated with Hunter Dickinson, Inc. (HDI), a diversified, global mining group with over 25 years of mineral development success. Rathdowney has their corporate headquarters in Vancouver, British Columbia.
The Company has interests in Poland, Alaska and Ireland. Rathdowney is advancing Project Olza (the contiguous Zawiercie, Rokitno and Chechlo concessions), a 150 square kilometer property located in the world-class Upper Silesian Mining District of Poland, which hosts premier Mississippi Valley-Type deposits. Due to the district's long mining history, extensive infrastructure is readily available to new projects. This includes power and smelter facilities. Rathdowney Resources' ground is linked by rail to these facilities.
In Alaska, Rathdowney has made a significant investment by acquiring an 18 percent interest in Heatherdale Resources Ltd. Heatherdale owns the high-grade polymetallic volcanic massive sulphide Niblack Project in southeast Alaska.
In Ireland, Rathdowney acquired eight properties and conducted early stage exploration, including geophysical and geochemical surveys. They followed up by initial drill testing of priority targets. This work attracted the attention of major mining companies Teck Resources and Antofagasta that have recently taken options to earn up to 100 percent interests on all of Rathdowney Resources' Irish properties. Rathdowney retains NSR royalties on any future production.
Last week, Rathdowney Resources announced the results for 24 holes from their ongoing drilling program in Poland. These new holes further demonstrate the strength and persistence of the zinc-lead mineralization at Project Olza. The current results are for holes OLZ-147, OLZ-159 and OLZ-179 to OLZ-200, located at drill centers in the northern, central and southern parts of the mineralized corridor at Project Olza.
The Company's drilling intersected high grades at Project Olza. This includes 27.3 m of 7.2 percent Zn+Pb in hole 147, 5.3 m of 9.2 percent Zn+Pb in hole 189 and 2.2 m of 36.1 percent Zn+Pb in hole 194.
Rathdowney Resources Ltd. (RTH.V), closed Tuesday's trading session at $0.49, up 2.08%, on 74,758 volume. The stock's 52-week low/high is $0.30/$0.58.
FindEx.com, Inc. (FIND)
SizzlingStockPicks, OTCPicks, Orbit Stocks, Stock Alerts, ChartAdvisor, and Fast Moving Stocks reported earlier on FindEx.com, Inc. (FIND), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
FindEx.com, Inc. is a retail, wholesale, and Internet supplier of software products to businesses and individuals. The Company's current operations consist exclusively of those relating to FormTool.com and its related line of products that the Company acquired in February 2008. Their current operations also consist of two language tutorial products. Founded in 1997, FindEx.com lists on the OTC Bulletin Board. The Company is based in Nebraska.
FormTool software provides professionally designed forms for business, accounting, construction, sales, real estate, human resource, as well as personal organization needs. The Company's FormTool Deluxe enables users to create a professional-looking form. It features drag-and-drop technology from start-to-finish.
A user can design a form from scratch, or use one of more than 800 included templates. FormTool has design, editing, routing, and filling capabilities. It also features a relational database. With FormTool, a user has popular Database Support. They can build a connection with popular databases such as Access, ACT, Excel, SQL, Oracle, and others. They can also Send/Receive forms through email.
A current principal focus of FindEx.com (beyond their current software business) surrounds the identification and evaluation of what they perceive as their best broader-range strategic options for realizing the most favorable economic outcome, and ultimately the selection and pursuit of one or more of those options.
Options under consideration have included the pursuit of a business combination transaction involving a potential merger or acquisition aimed at revenue re-development and long-term growth, and liquidation and/or winding-down, aimed in the very different direction of business cessation. Unless and until the Company determines to liquidate and/or wind down, they will continue to be largely focused on acquiring or merging with another operating company.
FindEx.com has formulated a plan to develop a new version of their FormTool software package. The Company hopes to release a new version of FormTool towards the end of the first quarter of 2013.
FindEx.com, Inc. (FIND), closed Tuesday's trading session at $0.0136, up 109.23%, on 1,228,944 volume with 43 trades. The average volume for the last 60 days is 38,278 and the stock's 52-week low/high is $0.0009/$0.015.
Stratex Oil & Gas Holdings, Inc. (STTX)
Wall Street Resources reported today on Stratex Oil & Gas Holdings, Inc. (STTX), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Stratex Oil & Gas Holdings, Inc. is an independent energy company whose shares trade on the OTC Markets: OTCQB. The Company focuses on the exploration, acquisition, and production of crude oil in the Bakken and Three Forks formations in North Dakota and Montana. Stratex's core operating areas are the Williston Basin in North Dakota and Montana, and the Denver-Julesburg Basin in Colorado. The Company works to retain operations on their lands wherever possible so they can control the timing of the development of their leasehold. Stratex Oil & Gas Holdings has their headquarters in Watertown, Connecticut.
The Company is primarily a non-operating participant. Stratex relies on operating partners to conduct the drilling process. The Company's management team structures their operations in a manner that minimizes operating and overhead costs as a leasehold interest owner.
The concentration of the Company's oil and natural gas operations are primarily in two Rocky Mountain basins: the Williston Basin of North Dakota and Montana, and the Green River Basin of Wyoming. Stratex's corporate strategy is to internally identify prospects, acquire lands encompassing those prospects, and evaluate those prospects using subsurface geology, geophysical data, and exploratory drilling. The Company has developed an oil portfolio of proven reserves, as well as development and exploratory drilling opportunities on high potential oil prospects, using this strategy.
In the Williston Basin, Stratex focuses on oil production from multiple zones including the Bakken Shale and Three Forks Sanish Formations. In the Denver-Julesberg Basin, the Company focuses on the Niobrara Formations.
Today, Stratex Oil & Gas Holdings announced the acquisition of multiple wells in North Dakota. Consideration paid for the wells was $250,000 in cash and 250,000 shares of Stratex common stock. The gross acreage is 3,850 and the net acreage position is 87.35. The acquired acreage includes 6 producing Bakken wells, 3 currently drilling wells, and permitted Bakken well locations with a number of additional possible permitted locations. All of the acreage is non-operated; the operators are Whiting Petroleum, XTO Energy and Continental Resources.
Stratex Oil & Gas Holdings, Inc. (STTX), closed Tuesday's trading session at $1.40, even for the day. The average volume for the last 60 days is 1,746 and the stock's 52-week low/high is $0.2857/$2.90.
BioPower Operations Corp. (BOPO)
Wall Street Resources reported today on BioPower Operations Corp. (BOPO), and we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.
BioPower Operations Corp. is a development stage renewable energy company that lists on the OTCQB. The Company focuses on growing biomass energy crops, coupled with the production and sale of biomass products and byproducts. BioPower's short-term plans are to produce and sell biomass oils that can also undergo conversion into oils, biofuels, animal feed or electricity. BioPower Operations has their corporate headquarters in Fort Lauderdale, Florida.
As pertains to their short-term plans, BioPower plans to grow castor for the production and sale of castor oil. The Company has started the process to obtain financing for a castor plantation and milling operation to supply castor oil. Their corporate goal is to achieve a first-to-market position in the United States and become a major supplier over the next three years. BioPower Operations hopes to realize revenues from this project in 2013. In addition, the Company intends to investigate and license and/or joint venture with the most promising, emerging biomass products, technologies and services.
BioPower has identified a hybrid seed that they believe may result in high yields per acre. They have identified unique growing protocols that also may enhance the yield of seed – therefore, oil by weight. The Company has identified engineering firms to prepare general and site-specific engineering for permitting and construction purposes.
They have identified the mill equipment to process the seed into oil and the agricultural equipment required to facilitate the growing protocols that have been identified. BioPower Operations is currently working on the development of a long-term (greater than one year) purchase agreement for the sale of castor oil.
Concerning their long-term plans, BioPower Operations has developed and licensed several long-term crops that their licensors have represented can be produced in large, sustainable quantities. The focus of these long-term solutions is the growing demand for alternatives to hydrocarbon products, energy independence, as well as declining fossil fuel resources. BioPower has licenses for growing long-term crops including Millettia Pinnata, Silver Leaf (Yellow Horn), Marjestica (Paulownia Hybrid), and Beema Bamboo.
BioPower Operations Corp. (BOPO), closed Tuesday's trading session at $0.12, up 2.13%, on 10,000 volume with 1 trade. The average volume for the last 60 days is 11,195 and the stock's 52-week low/high is $0.06/$0.75.
Viking Minerals, Inc. (VKML)
PennyTrader Publisher and We Beat Wallstreet reported previously on Viking Minerals, Inc. (VKML), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Peoria, Arizona, Viking Minerals, Inc. engages in the acquisition and development of near-term producing copper, gold, and silver properties in the U. S. and Canada. The Company is a pre-exploration stage enterprise that is currently seeking mineral claims for development. Viking Minerals' shares trade on the OTC Bulletin Board.
Viking has a large copper-rich land position in mining-friendly Nevada. The Company is concentrating on developing their Dolly Varden properties in northeastern Nevada, adjacent to the Victoria Copper mine. The large resource of copper in this region has been well documented and hosts two large operating mines ‒ Battle Mountain and Robinson.
The Dolly Varden Property consists of 16 contiguous mineral claims. These are situated close to Dolly Varden Springs. The Property is strategically located between The Kennecott Mine, the world's third largest copper gold mine, and Quadra's Robinson Mine, which produced more than 126 million pounds of copper and 81,000 ounces of gold. Viking Minerals' Dolly Varden Property is 200 acres.
The Dolly Varden area is in Elko County, Nevada, 50 miles north of Ely, Nevada. The Dolly Varden Property topography is typical of the Nevada foothills with ranges rising from the Dolly Varden spring at under 200 feet to more than 800 feet. Another type of deposit suggested, related to the copper skarns, is a gold copper porphyry system. The Company believes that the South Dolly Claims provide a very attractive exploration prospect for copper gold mineralization associated with known mineralizing porphyry intrusives.
Last week, Viking Minerals announced on behalf of the Board of Directors that the Company is in the evaluation process of identifying two new acquisitions in the Gold exploration and Oil & Gas sector. Currently, Viking Minerals has mining concessions in North and South America, the Company will decide in the coming weeks, to proceed with the exploration program on their concession in South America.
Today, Viking Minerals announced on behalf of the Board of Directors that they appointed Dr. Allan Rosenthal, Ph.D to the position of President & CEO. Mr. Charles Irizarry will remain a Director and will assume the responsibility of Chief Financial Officer. Dr. Rosenthal is a Ph.D. in Materials Science and Engineering, with expertise in management and operations in the mining space. He will initially focus on enabling Viking Minerals to acquire mining and Oil & Gas assets.
Viking Minerals, Inc. (VKML), closed Tuesday's trading session at $0.042, down 23.64%, on 208,850 volume with 20 trades. The average volume for the last 60 days is 83,945 and the stock's 52-week low/high is $0.01/$15.00.
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $8.30, up 1.34%, on 38,182 volume with 60 trades. The stock’s average daily volume over the past 60 days is 50,272, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.18, up 4.65%, on 163,400 volume with 19 trades. The stock’s average daily volume over the past 60 days is 118,295, and its 52-week low/high is $0.171/$0.69.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Latest Product Launch
International Stem Cell Corp Announces Third Quarter 2012 Financial Results
International Stem Cell Corporation to Host Third Quarter 2012 Financial Results Conference Call at 11:00 a.m. ET on Friday, November 9, 2012
VIASPACE, Inc. (VSPC)
The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.013, up 4.84%, on 906,400 volume with 14 trades. The stock’s average daily volume over the past 60 days is 1,596,431, and its 52-week low/high is $0.0013/$0.015.
VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.
The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.
VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.
The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer
VIASPACE, Inc. Company Blog
VIASPACE, Inc. News:
Board Chairman and CEO Conduct Interview With The Green Baron Report
VIASPACE, Inc. Announces Engagement of QualityStocks Investor Relations Services
Renewable Giant King Grass is Growing in St. Croix; VIASPACE Now on Facebook and Twitter
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0081, on 51,200 volume with 1 trade. The stock’s average daily volume over the past 60 days is 189,561, and its 52-week low/high is $0.001/$0.018.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
Consorteum Holdings Files Form 10-K Report With the Securities and Exchange Commission
CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
International Stem Cell Corp., developers of human parthenogenic stem cells (hpSCs), a new class of non-embryonic stem cells that has the best characteristics of each of the other classes of stem cells, is focused on using hpSCs to treat severe diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe, immune-matched human cells.
Parthenogenic stem cells hold great promise for stem cell regenerative medicine by addressing the critical issue of immune-rejection, the problem of finding cells that have the right chemical structure so as not to be rejected by the patient. Parthenogenesis utilizes unfertilized human eggs to create stem cells that can be immune-matched to millions of persons of differing sexes and racial backgrounds. As a result, a relatively small number of hpSC lines could provide sufficient immune-matched cells to cover large parts of the world’s population. This opens the possibility of successful treatment of those above mentioned diseases where cell therapy works but is severely restricted due to the problem of immune matching.
Each of these diseases and health needs represents a major potential market for ISCO:
• Brain diseases, such as Parkinson’s which is diagnosed in approximately 60,000 Americans annually
• Liver diseases, causing 30,000 U.S. deaths annually
• Cornea transplants, received by roughly 50,000 Americans each year
• Diabetes, suffered by over 25 million Americans
Globally, the figures associated with these diseases are far greater, even more so when considering the number of people in developing countries that need things like corneal transplants but never actually get them. ISCO is actively engaged in the pre-clinical stage of research and development for parthenogenic stem cell based treatments of these and other diseases.
For additional information, visit www.InternationalStemCell.com
EntreMed, a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. The article is titled “Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models.”
The reports state findings that ENMD-2076 was able to provide anticancer activity against breast cancer cell lines lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and without HER2‑amplification. Candidate predictive biomarkers were also identified which may be useful in selecting patients that are particularly sensitive to this compound, ENMD-2076, in the future.
Dr. Jennifer R. Diamond of the University of Colorado School of Medicine, who led the study, commented, “Triple-negative breast cancer is an aggressive breast cancer subtype which carries a high risk of developing metastasis. A major barrier to the successful treatment of metastatic TNBC is the lack of effective targeted anti-cancer agents. Through this study, we show that ENMD-2076 has activity against preclinical models of breast cancer with more robust activity against TNBC. The study also supports further clinical investigation of ENMD-2076 in patients with metastatic TNBC with an emphasis on the continued development of p53-based predictive biomarkers.”
The study was comprised of a diverse panel of twenty-nine breast cancer cell lines representative of the clinically defined breast cancer subtypes which were exposed to ENMD-2076. During the study, the effects on proliferation, apoptosis, and cell cycle distribution were evaluated. The study provided information that is the basis for a predictive biomarker strategy to explore in future clinical trials with ENMD-2076. In this study, ENMD-2076 demonstrated stronger activity against cell lines of the TNBC subtype compared to the luminal and HER2-amplified subtypes. This in vitro activity was confirmed in vivo, in MDA-MB-468 and MDA-MB-231 TNBC xenografts. Baseline gene expression profiling and pathway analysis of the panel revealed that p53 and G1/S cell cycle pathways were unregulated in the more sensitive cell lines. Within the TNBC subset, cell lines with a p53 mutation and increased p53 expression were more sensitive to the cytotoxic and pro-apoptotic effects of ENMD-2076 exposure than cell lines with decreased p53 expression.
Ken Ren, Ph.D., EntreMed’s Chief Executive Officer further commented, “One of the major challenges for the development of a target therapy for cancer is the identification of a responsive subtype with a predictive biomarker. In our previous Phase 1 study, we observed a patient with TNBC who had failed multiple chemotherapy regimens then had clinically significant stabilization of disease for 41 weeks after ENMD-2076 treatment. The benchmark of median duration after first line therapy in such patients with metastasis is just 12 weeks. This pre-clinical study illustrated scientific insight into the selective sensitivity of TNBC to ENMD-2076 with direct correlation to p53 mutation and over expression. It provides strong support for the rational of our ongoing Phase 2 TNBC trial. Upon further confirmation clinically, it may also provide guidance on future trials for patient selection, and may increase the probability of success. We are continuing to enroll patients in the ongoing Phase 2 trial and anticipate the initiation of a second site for this trial soon. We remain on track with our clinical development activities and expect our progress to accelerate in the coming months and year.”
EntreMed is a clinical-stage pharmaceutical company employing a global drug development strategy primarily in the United States and China. One of the company’s primary compounds, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.
For more information, visit www.entremed.com
Shoreline Energy Corp. is planning to hold a conference call tomorrow, November 28, 2012, to discuss its recent business developments, including the impact and outlook relating to its acquisition of the Wattenberg Colorado Project located in the Denver-Julesberg Basin.
The Wattenberg Colorado Project represents Shoreline’s initial entry into the United States. This project is currently an area of a large scale, low risk horizontal development well program, using multi-stage frac technology. Acquisition of the project is expected to generate $4.6m of cash flows the first year, providing an initial rate of return of more than 30%.
The CEO of Shoreline will be hosting the conference call. Those who wish to participate should dial in at 11:30am ET using 1-877-317-6776 with the conference ID 10021652. International callers should use the same conference code, but dial 1-412-317-0088 instead. The conference will also be available via webcast at the following link: http://webcast.mzvaluemonitor.com/Home/Login/648.
A slide presentation for the call will be available on the company’s website at the start of the call. After the prepared presentations, investors will be given the opportunity to ask questions.
Investors unable to attend at the scheduled time can access a recording of the call. To listen, call 1-877-344-7529 within the United States or 1-412-317-0088 when calling internationally. The replay pin number required to access the recording is 10021652.
For more information, visit www.shorelineenergy.ca
MediciNova received a notice of allowance from the European Patent Office for a pending patent application which covers the use of ibudilast (MN-166) for the treatment of progressive forms of multiple sclerosis (MS). MN-166 is the company’s drug development candidate for certain neurological conditions, including progressive MS, drug addiction, and pain. Patents maturing in this type of application are not expected to mature before 2029 and will cover multiple methods of treating primary or secondary progressive MS.
“Treatment options for patients who have progressive MS are very limited and assessing potential pharmacotherapies like ibudilast may offer real hope,” said Dr. Frederik Barkhof, professor of neuroradiology and medicine, VU Medical Center, Amsterdam.
The patent application is based upon clinical investigations conducted by MediciNova and collaborating researchers that showed adisease-modifying benefit. The benefit identified is that brain volume loss (brain atrophy) commonly associated with disease progression was demonstrated to be reduced by oral administration of ibudilast to a group of MS patients in a dose-related fashion over at least a 10-month treatment period. Ibudilast has been used in asthma and post-stroke disorders in Japan for about 20 years. MediciNova has demonstrated the potential utility of ibudilast in the treatment of neurological disorders at higher doses with encouraging outcomes in company-sponsored clinical trials in multiple sclerosis (MS) and neuropathic pain.
“We are very pleased with this positive step in our patent portfolio, It complements our strategy to advance MN-166 into Phase II proof-of-concept clinical development for progressive multiple sclerosis,” said Yuichi Iwaki, president and CEO of MediciNova.
MediciNova is a biopharmaceutical company that acquires and develops small-molecule therapeutics for the treatment of diseases. MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorder, preterm labor, and urinary incontinence, as well as two preclinical-stage compounds for the treatment of thrombotic disorders.
For more information on MediciNova, visit www.medicinova.com
Today's Top 3
The Stock Psycho
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences
- GreeneStone Healthcare Corp. (GRST) Seeks Amex Listing - New Report Confirms Demand
- International Stem Cell Corp. (ISCO) Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs
- Loans4Less.com, Inc. (LFLS) Provides Preliminary Financial Results for the Third Quarter of 2012
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- TNI BioTech Inc. (TNIB) and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
- VistaGen Therapeutics, Inc. (VSTA) Completes $3.25 Million Financing and $3.0 Million Debt Restructuring